Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling - Report - MDSpire

Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling

  • By

  • Feng-Xian Ni

  • Shao-Cong Ren

  • Jie Hu

  • Pei-Sheng Chen

  • Hui-Hui Chen

  • Dong-Hui Huang

  • Ze-Bo Jiang

  • June 23, 2026

  • 0 min

Share

Clinical Report: Necroptosis in Asthma: A Key Factor in Immune Dysfunction

Overview

This review highlights necroptosis as a significant mechanism in asthma pathophysiology, linking immune dysfunction and airway remodeling.

Background

Asthma is a complex chronic airway disease characterized by inflammation and airway remodeling. Traditional models focusing on Th2 immunity do not fully explain the disease's chronicity and treatment resistance.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

  • Necroptosis is a regulated form of cell death that contributes to inflammation in asthma.
  • Triggers such as allergens and pollutants can activate necroptosis in airway cells.
  • Necroptosis leads to the release of damage-associated molecular patterns (DAMPs).
  • Immune cell necroptosis contributes to a steroid-refractory environment in severe asthma cases.
  • The interplay between necroptosis, pyroptosis, and apoptosis is crucial in asthma pathophysiology.

Clinical Implications

Recognizing necroptosis as a key player in asthma may lead to the development of targeted therapies.

Conclusion

This review provides insights into the mechanisms underlying asthma's persistent inflammation and structural changes.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Necroptosis in Asthma: A Critical Driver of Immune Dysregulation and Airway
  2. Frontiers in Endocrinology — Bone health in asthma: a twofold effect of disease and pharmacotherapy
  3. Drug Safety — Evaluating the Safety of Benralizumab in Eosinophil-Depleting Treatment for Severe Eosinophilic Asthma
  4. Frontiers in Immunology — Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework
  5. conexiant — Airway Resistome Higher In Chronic Lung Disease
  6. 2026 GINA Strategy Report - Global Initiative for Asthma - GINA
  7. As-Needed Albuterol–Budesonide in Mild Asthma | New England Journal of Medicine
  8. Frontiers | Necroptosis in Asthma: A Critical Driver of Immune Dysregulation and Airway

Original Source(s)

Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling

  • by Feng-Xian Ni, Shao-Cong Ren, Jie Hu, Pei-Sheng Chen, Hui-Hui Chen, Dong-Hui Huang, Ze-Bo Jiang

  • June 23, 2026

Related Content

Eosinophil Counts, FeNO May Predict Asthma, COPD Exacerbations

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.